# Ainos, Inc.: Form 10-Q for the period ended Jun 30, 2010

- Company: [Ainos, Inc.](/companies/aimd.md) (CIK 1014763)
- Form: 10-Q
- Filed: 2010-08-23
- Accepted by EDGAR: Aug 23, 2010, 11:44 ET
- Period: 2010-06-30
- Accession: 0001014763-10-000006
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1014763/000101476310000006/form10q_063010.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1014763/000101476310000006/

## Management's discussion and analysis

As filed, 25,602 characters.

*The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report. The results shown herein are not necessarily indicative of the results to be expected in any future periods. This discussion contains forward-looking statements based on current expectations, which involve uncertainties. Actual results and the timing of events could differ materially from the forward-looking statements as a result of a number of factors. Readers should also carefully review factors set forth in other reports or documents that we file from time to time with the Securities and Exchange Commission.*

#### Company Goal – FDA Approval and Commercialization of Oral Interferon.

Amarillo Biosciences, Inc. (OTCBB: AMAR), is the world leader in the development of low-dose interferon for oral delivery and is conducting Phase 2 clinical studies testing oral interferon in animal and human diseases. We have changed our focus from Orphan Diseases (small markets) to treatment of diseases with large markets to attract large pharma partners. Our funding strategy is to seek private placement and partner funding to complete Phase 2 clinical studies for influenza, chronic cough in COPD patients, and hepatitis C; then seek large pharma partners to fund and help with the regulatory approval process in the US and Europe. We believe that our technology and the large, billion-dollar markets for these disease indications will attract global pharma partners sometime later this year or early next year.

#### Intellectual Property

Our portfolio consists of patents with claims that encompass method of use or treatment with interferon and composition of matter and manufacturing. We currently own or license six patents and two pending patents related to low-dose orally delivered interferon, and one issued patent on our dietary supplement. We have completed more than 100 pre-clinical (animal) and human studies of the safety and efficacy of low-dose orally delivered interferon.

#### Technology - Non-toxic Interferon

Injectable interferon is FDA-approved to treat some neoplastic, viral and autoimmune diseases. Many patients experience moderate to severe side effects that result in discontinuance of injectable interferon therapy. Our product is a natural human interferon alpha delivered into the oral cavity as a lozenge in low (nanogram) doses. The lozenge dissolves in the mouth where interferon binds to surface (mucosal) cells in the mouth and throat resulting in stimulation of immune mechanisms. Orally delivered interferon has been shown to activate hundreds of immune system genes in the peripheral blood. Human studies have shown that oral interferon is effective against viral and autoimmune diseases. Oral interferon is given in concentrations 10,000 times less than that given by injection, resulting in negligible side effects.

Governmental or FDA approval is required for our principal products. Our progress toward approval is discussed under each specific indication, below.

#### Influenza/Cold - FDA Phase 2 Study

Dr. Manfred Beilharz, Chair of Microbiology and Immunology, Biomolecular and Chemical Sciences at the University of Western Australia recently reported results of a Phase 2 clinical trial in Perth, Australia that showed low-dose interferon lozenges provide an effective, safe and economical form of prophylaxis against colds and influenza. Interferon lozenges were also shown in this study to enhance the effectiveness of seasonal influenza vaccine. We think the implications of this study should help us in attracting a global pharma partner.

#### Chronic Cough in COPD – FDA Phase 2 study ongoing; funding sought for a second study

COPD affects approximately 10% of the population over 40, is a growing problem, and is the 4th leading cause of death in the world. Chronic obstructive pulmonary disease (COPD) is a clinical condition with a progressive airflow limitation that is poorly reversible and characteristic of chronic bronchitis and emphysema. The causes of COPD include tobacco smoke, occupational dusts, chemicals, vapors and environmental pollutants. COPD is estimated to affect more that 600 million people worldwide. There are no effective therapies for emphysema, nor are there efficient clinical management strategies.

Data from a Phase 2 clinical study at Texas Tech University shows that treatment with oral interferon leads to a rapid and significant reduction in the cough associated with idiopathic pulmonary fibrosis (IPF), resulting in improved quality of life. IPF is similar to COPD in that both diseases lead to a chronic cough in the majority of sufferers through inflammation of the airways. A proof-of-concept study of low-dose oral interferon as treatment of chronic cough is ongoing at Texas Tech University. The study will evaluate the ability of oral interferon to reduce the frequency and severity of chronic cough, compared to placebo.

#### Hepatitis C - FDA Phase 2 study ongoing

CytoPharm, Inc., our licensee for Taiwan and China, is funding an ongoing Phase 2, placebo-controlled, dose-ranging study of 165 hepatitis C virus-infected patients in Taiwan. The study is designed to test the ability of oral interferon to reduce the virologic relapse rate of patients who have completed standard therapy with pegylated interferon plus ribavirin. Preliminary results are expected in the second half of 2011.

#### Oral Warts in HIV+ Patients – FDA Phase 2 study completed

Oral warts are lesions in the mouth caused by the human papillomavirus. The FDA has granted Orphan Drug Designation to us for interferon in the treatment of oral warts in HIV+ patients. In Phase 1/2 clinical studies of 36 HIV+ patients with multiple oral warts who were receiving highly active antiretroviral therapy (HAART), efficacy of oral interferon was observed when about 1/3 of the treated subjects achieved a complete or nearly complete regression of their warts.

In a Phase 2 double-blind follow-up study, 31% of evaluable subjects in the IFN group had a 75% or greater reduction in their mouth warts (complete response), compared to only 17% of the subjects in the placebo group. None of the subjects in the placebo group had a 75% or greater reduction in their lip warts, but 39% of the evaluable subjects in the IFN group met this criterion for complete response. However, given the small number of subjects with lip warts and the failure of the study to achieve full enrollment, neither of these differences in favor of IFN over placebo was statistically significant. Oral IFN treatment was found to be safe in this study as there were no increases in adverse event frequency or severity, compared to placebo.

#### Strategic Alliance with HBL

Hayashibara Biochemical Laboratories, Inc. (“HBL”) was established in 1970 to engage in research and development. It is a subsidiary of Hayashibara Company, Ltd., a privately-owned Japanese holding corporation with diversified subsidiaries. For more than 130 years, the Hayashibara Company, Ltd. and its predecessors have been applying microbiological technology to the starch industry for the production of maltose and other sugars.

In 1981, HBL established the Fujisaki Institute to accelerate development of industrial methods for the production of biologics and to sponsor clinical trials for such products. In 1985, HBL built the Fujisaki Cell Center to support basic research. In 1987, HBL successfully accomplished the mass production of human cells in an animal host by producing human cells in hamsters. This made it possible to economically produce a natural form of human interferon alpha and other biologics. HBL also has developed and obtained patents for technology relating to the production of interferon alpha-containing lozenges by which the stability of the interferon alpha activity can be maintained for up to 24 months at room temperature and up to five years if the product is refrigerated. We believe that the use of such lozenges gives us advantages over competitive technologies in terms of cost, taste and ease of handling. On March 13, 1992, we entered into a Joint Development and Manufacturing/

Supply Agreement with HBL (the “Development Agreement”). Such Development Agreement was subsequently amended on January 17, 1996; May 10, 1996; and September 7, 2001. The current expiration date of the Development Agreement is March 12, 2011, at which time it will automatically renew for an additional three (3) years, unless the parties agree otherwise. Among other things, the Development Agreement provides us with a source of natural human interferon alpha for use in the Company’s interferon alpha-containing products.

#### Strategic Alliance with Nobel.

We signed a licensing and supply agreement in September 2004 with a Turkish pharmaceutical company, NOBEL ILAC SANAYII VE TICARET A.S., providing the rights to oral low-dose interferon-alpha for the treatment of Behcet’s disease in Turkey and in Azerbaijan, Bosnia & Herzegovina, Bulgaria, Croatia, Georgia, Kazakhstan, Kyrghyzstan, Macedonia, Romania, Russia, Saudi Arabia, Slovenia, Tajikistan, Turkmenistan, Uzbekistan, and Federal Republic of Yugoslavia.

#### Strategic Alliance with Bumimedic.

In January 2006 we entered into a license and distribution agreement with Bumimedic (Malaysia) Sdn. Bhd, a Malaysian pharmaceutical company that is a part of the Antah HealthCare Group, to market our low-dose interferon (natural human IFN) in Malaysia. Bumimedic will seek registration for our natural human IFN and commence marketing the product after approval. The terms of the agreement call for Bumimedic to manufacture lozenges from our bulk natural human IFN (which is supplied by Hayashibara Biochemical Laboratories); package the lozenges and distribute them to local hospitals, pharmacies and clinics in Malaysia. Pursuant to the agreement, we will receive a series of payments, in three stages: upon formal execution of the distribution agreement, upon regulatory approval, and upon production. We will also receive a royalty on the sale of the natural human IFN.

#### Strategic Alliance with CytoPharm.

In November 2006, we entered into a License and Supply Agreement with CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization. Under the terms of the Agreement, CytoPharm and its subsidiary will conduct all clinical trials, and seek to obtain regulatory approvals in both China and Taiwan (the “Territory”) to launch our low dose oral interferon in the Territory for influenza and hepatitis B (“HBV”) and hepatitis C (“HCV”) indications. According to the Agreement, CytoPharm will make payments to us upon reaching certain milestones and will also pay royalties on low dose oral interferon sales in the Territory.

In March 2008, we entered into a Supply Agreement for Animal Health with CytoPharm, Inc. Under the terms of the Agreement, CytoPharm will conduct all clinical trials, and seek to obtain regulatory approvals in China and Taiwan (the “Territory”) to launch our low dose oral interferon in the Territory for treatment of diseases and other healthcare applications of swine, cattle and poultry. CytoPharm will make payments to us upon reaching certain milestones and will also pay royalties on low dose oral interferon sales in the Territory.

#### Strategic Alliance with Cyto Biotech.

On February 6, 2009, we entered into a 15-year License and Supply agreement with Cyto Biotech, Inc. a Taipei, Taiwan animal health company. Under the terms of the agreement, Cyto Biotech, will, at its sole expense and cost, conduct all clinical trials and studies and seek to obtain regulatory approvals in China, Taiwan, Thailand, the Philippines, Cambodia, Vietnam and Malaysia ("the Territory”), subject to the existing license and supply agreements with CytoPharm, Inc. and Bumimedic SDN. BHD., required for the commercial launch of our low dose oral interferon in the Territory for any animal and human health indications.

Cyto Biotech purchased common stock, included in the above issuances in Amarillo Biosciences stock; paid an initial license fee to us; and will pay a net royalty on low dose oral interferon sales. In addition, the agreement calls for certain minimum royalty payments to be made.

#### Strategic Alliance with Intas Pharmaceuticals.

On January 7, 2010, we entered into a License and Supply agreement with Intas Pharmaceuticals Ltd., an India-based pharmaceutical company with three decades of experience in the healthcare industry and a global presence in 42 countries worldwide. Under the terms of the agreement, Intas will pay the Company a royalty on net sales in India and Nepal after marketing approval is obtained.

*Nutraceutical Product.* We sell anhydrous crystalline maltose (ACM) as Maxisal® to individuals and to pharmacies in the USA and to licensed distributors overseas. We seek to out-license Maxisal®.

*Equity Funding.* In the first quarter of 2010, the Company sold 1,060,000 unregistered shares of common stock for $0.10 per share plus 1,060,000 3-year warrants with $0.10 exercise price. Net proceeds from private placement stock sales totaled $103,000 after payment of $3,000 in commissions. The Board extended incentives encouraging option and warrant holders to exercise options and warrants until January 22, 2010. An officer and a consultant exercised 82,000 options at $0.10 per share to purchase 82,000 shares of unregistered common stock. The officer and consultant also exercised a total of 163,000 cashless options at $0.10 per share resulting in the issuance of 70,258 unregistered shares of common stock with 92,742 shares of common stock previously held in reserve for options returned to the Treasury. The incremental fair value of the option exercise inducement was $4,456, which was recognized as an expense. Net proceeds from the private placement stock sales and option exercises totaled $111,200 during the first quarter of 2010. Two consultants were issued 135,814 registered shares and 10,000 unregistered shares of common stock for $18,080 and $1,050 of services, respectively.

In the second quarter of 2010, the Company sold 1,075,000 unregistered shares of common stock for $0.10 per share plus 1,075,000 3-year warrants with $0.10 exercise price. Net proceeds from private placement stock sales totaled $97,000 after payment of $10,500 in commissions. One consultant was issued 90,343 shares of common stock in exchange for $8,630 of services.

Results of Operations for Quarters Ended June 30, 2010 and 2009:

Revenues. During the quarter ended June 30, 2010, $3,024 from dietary supplement sales compared to $96 of dietary supplement sales only for the quarter ended June 30, 2009, an increase of $2,928. During the quarter ended June 30, 2010, no sublicense fee was generated compared to $13 sublicense fee the quarter ended June 30, 2009.

Research and Development Expenses. Research and development expenses of $97,831 were incurred for the quarter ended June 30, 2010, compared to $108,986 for the quarter ended June 30, 2009, a decrease of $11,155 (10%). The decrease was because oral warts and influenza were mostly completed in 2009. The costs consisted primarily of personnel and insurance costs.

Selling, General and Administrative Expenses. Selling, general and administrative expenses of $137,403 were incurred for the second quarter in 2010, compared to $434,564 for the second quarter of 2009, a decrease of $297,161 (68%). Most of this decrease was from lower employee and director compensation costs in the second quarter of 2010.

Change in Fair Value of Derivative Instruments. Change in fair value of derivative instruments was realized as a $784,056 gain in the second quarter of 2010 compared to $1,867,012 loss in the second quarter of 2009. Derivative liabilities decreased $2,651,068 from June 30, 2009 to June 30, 2010 mostly because our stock price declined from $0.17 on June 30, 2009 to $0.07 on June 30, 2010.

Other Income. During the three-month period ended June 30, 2010, $140 of interest and other income was generated compared to $1,431 from interest and other income for the quarter ended June 30, 2009. During the second quarter of 2009, interest and other income was mostly derived from the sale of office furniture.

Net Operating Loss. In the three-month period ended June 30, 2010, the Company's net operating loss was $234,248 compared to a net operating loss for the three-month period ended June 30, 2009 of $543,476, a $309,228 (57%) reduction. The operating loss was lower mostly because compensation costs for employees and directors were lower in the first three months of 2010.

Net Income (Loss). In the three-month period ended June 30, 2010, net income was $526,373 compared to a net loss for the three-month period ended June 30, 2009 of $2,431,912, an increase in net income of $2,958,285 (122%). This reduction was mostly the $2,651,068 difference in derivative gains in the second quarter of 2010 and derivative losses in the second quarter of 2009. The $297,161 reduction in general and administrative costs during the second quarter of 2010 compared to the second quarter of 2009 also contributed to the difference.

Results of Operations for the Six Months Ended June 30, 2010 and June 30, 2009

Revenues. During the six months ended June 30, 2010, $3,120 from dietary supplement sales were generated compared to $228 of dietary supplement sales only for the six months ended June 30, 2009, an increase of $2,892. During the six months ended June 30, 2010, no sublicense fee was generated compared to $795 sublicense fees the six months ended June 30, 2009.

Research and Development Expenses. Research and development expenses of $199,119 were incurred for the six month period ended June 30, 2010, compared to $279,937 for the six month period ended June 30, 2009, a decrease of $80,818 (29%). Research and development costs were lower the first six months of 2010 because oral warts in HIV+ patients and influenza studies were mostly completed in 2009. The costs consisted primarily of personnel and insurance costs.

Selling, General and Administrative Expenses. Selling, general and administrative expenses of $312,567 were incurred for the six-month period ended June 30, 2010, compared to $682,088 for the six-month period ended June 30, 2009, a decrease of $369,521 (54%). General and administrative expenses were lower in the six months ended June 30, 2010 mostly because compensation costs for employees and directors were $372,386 (71%) lower than in the first six months of 2009.

Change in Fair Value of Derivative Instruments. Change in fair value of derivative instruments was realized as an $847,790 gain for the six-month period ended June 30, 2010 compared to $1,991,736 loss in the six-month period ended June 30, 2009. Derivative liabilities decreased $2,839,526 from

June 30, 2009 to June 30, 2010 mostly because our stock price declined from $0.17 on June 30, 2009 to $0.07 on June 30, 2010.

Interest and Other Income. During the six-month period ended June 30, 2010, $140 of interest and other income was generated compare to $3,391 in the six-month period ended June 30, 2009, a decrease of $3,251(96%). Interest and other income was higher during the first six months of 2009 mostly because the Company sold some office furniture.

Net Operating Loss. In the six-month period ended June 30, 2010, the Company's net operating loss was $510,661 compared to a net operating loss for the six-month period ended June 30, 2009 of $961,453, a $450,792 (47%) reduction. The operating loss was lower mostly because general and administrative compensation costs for employees and directors were $372,386 lower in the first six months of 2010. Also, Research and development costs were $80,818 lower in the first six months of 2010.

Net Income (Loss). In the six-month period ended June 30, 2010, net income was $290,926 compared to a net loss for the six-month period ended June 30, 2009 of $2,995,508, an increase in net income of $3,286,434 (110%). The increase was mostly the $2,839,526 difference in derivative gains in the first six months of 2010 and derivative losses in the first six months of 2009. The $372,386 reduction in general and administrative costs during the first six months of 2010 compared to the first six months of 2009 also contributed to the difference.

Liquidity Needs: On June 30, 2010, the Company had available $21,300 cash and had a working capital deficit (current assets less current liabilities) of $4,253,715. Current liabilities include two $1 million notes, $705,924 of accrued interest and $78,360 of accrued expenses owed to Hayashibara Biochemical Laboratories, Inc. (HBL), the Company’s second largest shareholder. Accrued payroll and vacation expenses owed mostly to officers is $263,591. Derivative liabilities from warrants with embedded variable features valued at $1,080,330 are also included in the working capital deficit. That leaves approximately $125,510 of accounts payables and accrued expenses in the working capital deficit.

Assuming there is no decrease in current accounts payable, and accounting for various one–time expenses, the Company’s negative cash flow for operating activities plus equipment purchases and patent filings, the Company’s cash burn rate is approximately $61,000 per month (excluding approximately $4,600 per month of consultant fees paid in stock). The Company's continued losses and lack of liquidity raise substantial doubt about whether the Company is able to continue as a going concern for a reasonable period of time. The Company's ability to continue as a going concern is dependent upon several factors including, but not limited to, the Company's ability to generate sufficient cash flows to meet its obligations on a timely basis, obtain license and milestone fees, obtain additional financing and continue to obtain supplies and services from its vendors. The Company will need to raise additional funds in order to fully execute its 2010 Plan. The Company is currently pursuing potential investors for funding. In addition, the Company is also pursuing potential pharmaceutical partners to provide upfront license fee payments and funding for clinical studies. There can be no assurance that private placement funding or pharmaceutical partner funding will become available.

Forward-Looking Statements: Certain statements made in this Plan of Operations and elsewhere in this report are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance, achievements, costs or expenses and may contain words such as "believe," "anticipate," "expect," "estimate," "project," "budget," or words or phrases of similar meaning. Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from those projected in the forward-looking statements. Such risks and uncertainties are detailed from time to time in reports filed by the Company with the Securities and Exchange Commission, including Forms 8-K, 10-Qand 10-K and include among others the following: promulgation and implementation of regulations by the U.S. Food and Drug Administration ("FDA"); promulgation and implementation of regulations by foreign governmental instru­mentalities with functions similar to those of the FDA; costs of research and development and clinical trials, including without limitation, costs of clinical supplies, packaging and inserts, patient recruitment, trial monitoring, trial evaluation and publication; and possible difficulties in enrolling a sufficient number of qualified patients for certain clinical trials. The Company is also dependent upon a broad range of general economic and financial risks, such as possible increases in the costs of employing and/or retaining qualified personnel and consultants and possible inflation which might affect the Company's ability to remain within its budget forecasts. The principal uncertainties to which the Company is presently subject are its inability to ensure that the results of trials performed by the Company will be sufficiently favorable to ensure eventual regulatory approval for commercial sales, its inability to accurately budget at this time the possible costs associated with hiring and retaining of additional personnel, uncertainties regarding the terms and timing of one or more commercial partner agreements and its ability to continue as a going concern.

The risks cited here are not exhaustive. Other sections of this report may include additional factors which could adversely impact the Company's business and future prospects. Moreover, the Company is engaged in a very competitive and rapidly changing industry.

New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company's business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those projected in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual future events.

## Market risk

As filed, 13,164 characters.

*We may not be able to adequately protect and maintain our intellectual property.* Our success will depend in part on our ability to protect and maintain our patents, intellectual property rights and licensing arrangements for our products and technology. We currently own three patents and license seven patents. No assurance can be given that such licenses or rights used by us will not be challenged, infringed or circumvented or that the rights granted thereunder will provide competitive advantages to us. Furthermore, there can be no assurance that we will be able to remain in compliance with our existing or future licensing arrangements. Consequently, there may be a risk that licensing arrangements are withdrawn with no penalties to the licensee or compensation to us.

*We rely on third parties for the supply, manufacture and distribution of our products.* Third parties manufacture and distribute all of our products. We do not currently have manufacturing facilities or personnel to independently manufacture our products. Currently, Marlyn Nutraceutical manufactures our nutraceutical products. Our licensed distributors, located in the United States and internationally, distribute the products. Except for any contractual rights and remedies that we may have with our manufacturer and our distributors, we have no control over the availability of our products, their quality or cost or the actual distribution of our products. If for any reason we are unable to obtain or retain third-party manufacturers and distributors on commercially acceptable terms, we may not be able to produce and distribute our products as planned. If we encounter delays or difficulties with our contract manufacturer in producing or packaging our products or with our distributor in distributing our products, the production, distribution, marketing and subsequent sales of these products would be adversely affected, and we may have to seek alternative sources of supply or distribution or abandon or sell product lines on unsatisfactory terms. We may not be able to enter into alternative supply, production or distribution arrangements on commercially acceptable terms, if at all. There can be no assurance that the manufacturer that we have engaged will be able to provide sufficient quantities of these products or that the products supplied will meet with our specifications or that our distributor will be able to distribute our products in accordance with our requirements.

*We are dependant on funding from private placements of stock.* Our sales revenue, sublicense fees and royalty income are negligible compared to expenses. Our primary focus is to achieve FDA approval of oral interferon for one or more disease indications. We do not expect significant sales or royalty revenue in the near term as Phase 2 and Phase 3 clinical studies must be completed before a NDA (New Drug Application) may be submitted to the FDA. We operate at a net loss and current liabilities exceed current assets by $4,253,715. The working capital deficit includes two $1 million notes, $705,924 of accrued interest and $78,360 of accrued expenses owed to our second largest shareholder (HBL); $263,591 of accrued payroll and vacation expenses owed mostly to officers; and $1,080,330 of non-cash derivative liabilities for warrants with embedded derivatives. The remaining working capital deficit of approximately $125,510 consists of accounts payable and accrued expenses.

The Company is currently pursuing potential investors for funding. In addition the Company is also pursuing potential pharmaceutical partners to provide upfront license fee payments and funding for clinical studies. There can be no assurance that private placement funding or pharmaceutical partner funding will become available.

*We are dependent on certain key existing and future personnel.* Our success will depend, to a large degree, upon the efforts and abilities of our officers and key management employees such as Dr. Joseph M. Cummins, our President and Chief Executive Officer, Bernard Cohen, our Chief Financial Officer, and Martin J. Cummins, our Vice President of Clinical and Regulatory Affairs. The loss of the services of one or more of our key employees could have a material adverse effect on our operations. We do currently have employment agreements with our executive officers. We do not currently maintain key man life insurance on any of our key employees. In addition, as our business plan is implemented, we will need to recruit and retain additional management and key employees in virtually all phases of our operations. We cannot assure that we will be able to successfully attract and retain key personnel.

*If we do not successfully develop, acquire or license new drugs our business may not grow.* We must invest substantial time, resources and capital in identifying and developing new drugs, dosage and delivery systems, either on our own or by acquiring and licensing such products from third parties. Our growth depends, in part, on our success in such process. If we are unable to either develop new products on our own or acquire licenses for new products from third parties, our ability to grow revenues and market share may be adversely affected. In addition, we may not be able to recover our investment in the development of new drugs, given that projects may be interrupted, unsuccessful, not as profitable as initially contemplated or we may not be able to obtain necessary financing for such development if we are unable to fund such development from our future revenues. Similarly, there is no assurance that we can successfully secure such rights from third parties on an economically feasible basis.

*Our competitors are much larger and more experienced than we are and, even if we complete the development of our drugs, we may not be able to successfully compete with them.* The pharmaceutical industry is highly competitive. Our biologics and low-dose oral interferon alpha applications compete with high dose injectable interferon manufactured by Roche, Schering, InterMune, Serono, Biogen, and Berlex. High dose injectable interferon has been widely accepted by the medical community for many years. Companies who manufacture injectable interferon alpha applications are more established than we are and have far greater financial, technical, research and development, sales and marketing, administrative and other resources than we do. Even if we successfully complete the development of our tests, we may not be able to compete effectively with these much larger companies and their more established products.

*We have been the subject of a going concern opinion by our independent auditors who have raised substantial doubt as to our ability to continue as a going concern.* Our Independent Registered Public Accounting firm has added an explanatory paragraph to their audit reports issued in connection with our financial statements for December 31, 2009 and 2008 which states that our recurring losses from operations and the need to raise additional financing in order to execute our business plan raise substantial doubt about our ability to continue as a going concern. We have experienced a net income of $290,926 for the six months ended June 30, 2010 and a net loss of $2,995,508 for the six months ended June 30, 2009. The operating loss for the six months ended June 30, 2010 was $510,661 but was offset by a non-cash accounting gain of $847,790 from the change in fair value of derivative instruments. In addition, as of June 30, 2010 we had an accumulated deficit of $35,028,013. These factors, among others, raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustment that might result from the outcome of this uncertainty. Assurances cannot be given that adequate financing can be obtained to meet our capital needs. We have already significantly curtailed operations, and if we are unable to generate profits and if we to continue to be unable to obtain financing to meet our working capital requirements, we will have to cease operations altogether. Our continuation as a going concern is dependent upon our ability to generate sufficient cash flow to meet our obligations on a timely basis, to retain our current financing, to obtain additional financing, and, ultimately, to attain profitability.

*Risk Relating to Our January 2008 Financing Arrangement.* There are 12,477,999 shares underlying our warrants related to our January 2008 financing arrangement that may be available for future sale and the sale of these shares may depress the market price of our common stock. In addition the warrants have an anti-dilution ratchet feature that could cause the number of warrants to increase and the exercise price to decrease if we should have any non exempt stock, option or warrant issuances less the $0.10 per share. As of June 30, 2010, we had 54,564,416 shares of common stock issued and outstanding plus 26,712,096 shares reserved for options and warrants which includes the above January 2008 warrants.

*Risks Related to our Common Stock.* There is only a limited market for our common stock and the price of our common stock may be affected by factors that are unrelated to the performance of our business. If any of the risks described in these Risk Factors or other unseen risks are realized, the market price of our common stock could be materially adversely affected. Additionally, market prices for securities of biotechnology and diagnostic companies have historically been very volatile. The market for these securities has from time to time experienced significant price and volume fluctuations for reasons that are unrelated to the operating performance of any one company. In particular, and in addition to the other risks described elsewhere in these Risk Factors, the following factors can adversely affect the market price of our common stock:

- announcements of technological innovation or improved or new diagnostic products by others;
- general market conditions;
- changes in government regulation or patent decisions;
- changes in insurance reimbursement practices or policies for diagnostic products.

Our common shares have traded on the Over the Counter Bulletin Board at prices below $5.00 for several years. As a result, our shares are characterized as “penny stocks” which could adversely affect the market liquidity of our common stock. The Securities Enforcement and Penny Stock Reform Act of 1990 requires additional disclosure relating to the market for penny stocks in connection with trades in any stock defined as a penny stock. Securities and Exchange Commission regulations generally define a penny stock to be an equity security that has a market price of less than $5.00 per share, subject to certain exceptions. Such exceptions include any equity security listed on NASDAQ or a national securities exchange and any equity security issued by an issuer that has:

- net tangible assets in excess of $2,000,000, if such issuer has been in continuous operation for three years;
- net tangible assets in excess of $5,000,000, if such issuer has been in continuous operation for less than three years; or
- average revenue of at least $6,000,000, for the last three years.

Unless an exception is available, the regulations require, prior to any transaction involving a penny stock, that a disclosure schedule explaining the penny stock market and the risks associated therewith is delivered to a prospective purchaser of the penny stock. We currently do not qualify for an exception, and, therefore, our common stock is considered to be penny stock and is subject to these requirements. The penny stock regulations adversely affect the market liquidity of our common shares by limiting the ability of broker/dealers to trade the shares and the ability of purchasers of our common shares to sell in the secondary market. In addition, certain institutions and investors will not invest in penny stocks.

Future sales of a significant number of shares of our common stock by existing stockholders may lower the price of our common stock, which could result in losses to our stockholders. Approximately 2,300,000 restricted shares were issued during the six months ended June 30, 2010 which, upon becoming freely tradable under Rule 144 or 144(k) of the Securities Exchange Act of 1934, may lower the price of our common stock. The number of shares of restricted stock issued prior to September 1, 2009 that has been held for at least six months and hasn’t had the legends removed to become freely tradable under Rule 144 or 144(k) is not known.

The Company continues to pursue a broad range of financing alternatives to improve its financial condition. These alternatives may include the sale or issuance of a substantial amount of common stock, common stock warrants or stock options. These financing alternatives could require an increase in the number of authorized shares of the Company’s common stock and result in significant dilution to existing shareholders and, possibly, a change of control of the Company.

## Controls and procedures

As filed, 1,695 characters.

As required by Rule 13a-15 under the Exchange Act, we have carried out an evaluation of the effectiveness of the design and operation of our company’s disclosure controls and procedures as of the end of the period covered by this quarterly report, being June 30, 2010. This evaluation was carried out under the supervision and with the participation of our company’s management, including our company’s president and chief executive officer. Based upon that evaluation, our company’s president and chief executive officer concluded that our company’s disclosure controls and procedures are effective as at the end of the period covered by this report. There have been no significant changes in our company’s internal controls or in other factors, which could significantly affect internal controls subsequent to the date we carried out our evaluation.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Exchange Act is accumulated and communicated to management, including our company’s president and chief executive officer as appropriate, to allow timely decisions regarding required disclosure.

There were no changes in internal controls over financial reporting during the period ended June 30, 2010.

Filed Aug 23, 2010.
Source: SEC EDGAR, the filing index for accession 0001014763-10-000006. Last ingested by Listed: Nov 11, 2026, 00:28 ET. No prices; not investment advice.
